NextPoint CMO Leena Gandhi, MD, PhD, will attend #ESMO2026 in Madrid, October 23–27. We look forward to discussing our B7-H7-targeted pipeline, including T cell engagers, ADCs and checkpoint inhibitors, and connecting with the oncology community.

NextPoint Therapeutics CEO Ivan Cheung will attend the Goldman Sachs Healthcare Private Company Conference on October 19 in NYC. Attending? Connect with Ivan to learn more about our approach to developing novel cancer immunotherapies targeting B7-H7. #ImmunoOncology

NextPoint will participate in the Needham Private Biotech & MedTech Virtual 1×1 Forum, Oct. 13–14. CEO Ivan Cheung looks forward to connecting with investors and sharing updates on NextPoint. Interested in meeting with Ivan? Please reach out!

NextPoint CSO Tatiana Novobrantseva, Ph.D., will be speaking at the World Bispecific Summit with an Industry Leaders Panel, followed by a presentation on NextPoint’s approach to B7-H7 and the development of NPX372. Attending? Let's connect! #WorldBispecificSummit

Executive Director Matthew Rausch, PhD, is presenting a poster atSITC Spring Scientific meeting. The poster explores the biology of the B7-H7 pathway and its potential to enhance T-cell–mediated anti-tumor responses. Reach out if you want to connect! #SITC

#InternationalWomensDay may have passed, but we’re still celebrating the women whose expertise and leadership drive our work at NextPoint. A snapshot of the people behind the science advancing precision immuno-oncology. #WomenInScience #WomenInBiotech

In Scrip’s “What Does 2026 Hold for Biopharma?” outlook, Tatiana Novobrantseva, CSO of NextPoint Therapeutics, shares her view on where oncology differentiation is headed, novel targets, deep biology, and modality-agnostic precision. Read more: bit.ly/4qXtqz2

Clinical entry of NPX372, a first-in-class B7-H7–targeted T cell engager, following U.S. IND clearance. The first-in-human study pairs an IgG-like CD3 bispecific with biomarker-driven patient selection to enable rapid clinical readouts in solid tumors. bit.ly/4bPxSvf

A look at CEO Ivan Cheung presenting at the JP Morgan Conference. Ivan shared our precision oncology strategy across T cell engager, ADC and checkpoint inhibitor, grounded in B7-H7 science and biomarker-driven patient selection. Energized by conversations and year ahead.

Jamie Strand, Ph.D., VP of Technical Operations, will speak at the CMC Strategy Forum North America on Jan 26, sharing how protein engineering and CMC-driven cell-line development support consistent, manufacturable B7-H7 biologics ready for the clinic. #CASSS #CMCNA2026

Ivan Cheung, CEO of NextPoint Therapeutics, will present at the 2026 J.P. Morgan Healthcare Conference on Jan 15 at 8:30 am in San Francisco. NextPoint is advancing precision therapeutics across multiple modalities targeting B7-H7.  #JPM2026

Data from NextPoint Therapeutics at #AACR-NCI-EORTC! NPX125, a B7-H7–targeting ADC, shows potent anti-tumor activity across solid tumor models. Reinforcing the promise of B7-H7 as a next-generation ADC target.